Update on cardiovascular prevention in clinical practice: A position paper of the European Association of Preventive Cardiology of the European Society of Cardiology
Open accessThe DOI matches its Crossref record; 62 of the 62 references it cites were found in a registry or an index.
Abstract
European guidelines on cardiovascular prevention in clinical practice were first published in 1994 and have been regularly updated, most recently in 2016, by the Sixth European Joint Task Force. Given the amount of new information that has become available since then, components from the task force and experts from the European Association of Preventive Cardiology of the European Society of Cardiology were invited to provide a summary and critical review of the most important new studies and evidence since the latest guidelines were published. The structure of the document follows that of the previous document and has six parts: Introduction (epidemiology and cost effectiveness); Cardiovascular risk; How to intervene at the population level; How to intervene at the individual level; Disease-specific interventions; and Settings: where to intervene? In fact, in keeping with the guidelines, greater emphasis has been put on a population-based approach and on disease-specific interventions, avoiding re-interpretation of information already and previously considered. Finally, the presence of several gaps in the knowledge is highlighted.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
RETRACTED: Relationship between Clinic and Ambulatory Blood-Pressure Measurements and Mortality
Banegas, J. R., Ruilope, L. M., de la Sierra, A., Vinyoles, E., Gorostidi, M., de la Cruz, J. J., Ruiz-Hurtado, G., Segura, J., Rodríguez-Artalejo, F., & Williams, B. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1712231 · Cited by 490
RetractedHeart Disease and Stroke Statistics—2017 Update: A Report From the American Heart Association
Benjamin, E. J., Blaha, M. J., Chiuve, S. E., Cushman, M., Das, S. R., Deo, R., de Ferranti, S. D., Floyd, J., Fornage, M., Gillespie, C., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000485 · Cited by 12,591
Dabigatran versus warfarin in patients with atrial fibrillation
Connolly, S. J., Ezekowitz, M. D., Yusuf, S., Eikelboom, J., Oldgren, J., Parekh, A., Pogue, J., Reilly, P. A., Themeles, E., Varrone, J., et al. (2009) · New England Journal of Medicine · doi:10.1056/nejmoa0905561 · Cited by 11,215
2018 ESC/ESH Guidelines for the management of arterial hypertension
Williams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehy339 · Cited by 10,286
Self-citationThe Physical Activity Guidelines for Americans
Piercy, K. L., Troiano, R. P., Ballard, R. M., Carlson, S. A., Fulton, J. E., Galuska, D. A., George, S. M., & Olson, R. D. (2018) · JAMA · doi:10.1001/jama.2018.14854 · Cited by 9,755
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation
Patel, M. R., Mahaffey, K. W., Garg, J., Pan, G., Singer, D. E., Hacke, W., Breithardt, G., Halperin, J. L., Hankey, G. J., Piccini, J. P., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1009638 · Cited by 9,430
Apixaban versus warfarin in patients with atrial fibrillation
Granger, C. B., Alexander, J. H., McMurray, J. J. V., Lopes, R. D., Hylek, E. M., Hanna, M., Al-Khalidi, H. R., Ansell, J., Atar, D., Avezum, A., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1107039 · Cited by 8,943
European Guidelines on cardiovascular disease prevention in clinical practice (version 2012)
Authors/Task Force Members:, Perk, J., De Backer, G., Gohlke, H., Graham, I., Reiner, Ž., Verschuren, M., Albus, C., Benlian, P., Boysen, G., et al. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehs092 · Cited by 8,490
Self-citationForouzanfar, M. H., Afshin, A., Alexander, L. T., Anderson, H. R., Bhutta, Z. A., Biryukov, S., Brauer, M., Burnett, R., Cercy, K., Charlson, F. J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)31679-8 · Cited by 7,698
Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction
McMurray, J. J. V., Solomon, S. D., Inzucchi, S. E., Køber, L., Kosiborod, M. N., Martinez, F. A., Ponikowski, P., Sabatine, M. S., Anand, I. S., Bělohlávek, J., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1911303 · Cited by 7,140
2016 European Guidelines on cardiovascular disease prevention in clinical practice
Piepoli, M. F., Hoes, A. W., Agewall, S., Albus, C., Brotons, C., Catapano, A. L., Cooney, M.-T., Corrà, U., Cosyns, B., Deaton, C., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehw106 · Cited by 6,457
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Edoxaban versus warfarin in patients with atrial fibrillation
Giugliano, R. P., Ruff, C. T., Braunwald, E., Murphy, S. A., Wiviott, S. D., Halperin, J. L., Waldo, A. L., Ezekowitz, M. D., Weitz, J. I., Špinar, J., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1310907 · Cited by 5,164
Cosentino, F., Grant, P. J., Aboyans, V., Bailey, C. J., Ceriello, A., Delgado, V., Federici, M., Filippatos, G., Grobbee, D. E., Hansen, T. B., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz486 · Cited by 4,763
Self-citationAlirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1801174 · Cited by 3,634 · cited 2×
“001), with a greater absolute benefit among patients with higher baseline LDL-cholesterol levels.(140) In both studies no increase in new-onset DM or worsening of glycaemic parameters were observed, nor was there evidence of an adverse effect on cognitive function or the risk of cancer.”
BackgroundCardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia
Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Doyle, R. T., Juliano, R. A., Jiao, L., Granowitz, C., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1812792 · Cited by 3,317
Kapur, V. K., Auckley, D. H., Chowdhuri, S., Kuhlmann, D. C., Mehra, R., Ramar, K., & Harrod, C. G. (2017) · Journal of Clinical Sleep Medicine · doi:10.5664/jcsm.6506 · Cited by 3,253 · cited 1×
“Alternatively, an apnoea–hypopnea index of 15 or greater is treated as OSA, even in the absence of signs, symptoms or associated medical conditions.(49) Treatment of OSA with continuous positive airway pressure (CPAP) may improve patient-reported outcomes such as sleepiness, quality of life and mood, but evidence on t…”
BackgroundZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., Furtado, R. H. M., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)32590-x · Cited by 2,845
Ekelund, U., Steene-Johannessen, J., Brown, W. J., Fagerland, M. W., Owen, N., Powell, K. E., Bauman, A., & Lee, I.-M. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30370-1 · Cited by 2,648
Lean, M. E., Leslie, W. S., Barnes, A. C., Brosnahan, N., Thom, G., McCombie, L., Peters, C., Zhyzhneuskaya, S., Al-Mrabeh, A., Hollingsworth, K. G., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)33102-1 · Cited by 2,095 · cited 1×
“The amount of weight loss was associated with DM remission, as 86% of those who lost 15 kg or greater achieved remission in the first year compared to 34% of those with 5–10 kg weight loss.(29) While most guidelines prioritise the use of intensive risk factor management in people with type 2 DM above the age of 40 yea…”
BackgroundSelf-citationPrevention of bleeding in patients with atrial fibrillation undergoing PCI
Gibson, C. M., Mehran, R., Bode, C., Halperin, J., Verheugt, F. W., Wildgoose, P., Birmingham, M., Ianus, J., Burton, P., van Eickels, M., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1611594 · Cited by 1,590
Arem, H., Moore, S. C., Patel, A., Hartge, P., Berrington de Gonzalez, A., Visvanathan, K., Campbell, P. T., Freedman, M., Weiderpass, E., Adami, H. O., et al. (2015) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2015.0533 · Cited by 1,498
Coronary CT Angiography and 5-Year Risk of Myocardial Infarction
The SCOT-HEART Investigators (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1805971 · Cited by 1,390
Dietary fats and cardiovascular disease: a presidential advisory from the American Heart Association
Sacks, F. M., Lichtenstein, A. H., Wu, J. H. Y., Appel, L. J., Creager, M. A., Kris-Etherton, P. M., Miller, M., Rimm, E. B., Rudel, L. L., Robinson, J. G., et al. (2017) · Circulation · doi:10.1161/cir.0000000000000510 · Cited by 1,386
Dual antithrombotic therapy with dabigatran after PCI in atrial fibrillation
Cannon, C. P., Bhatt, D. L., Oldgren, J., Lip, G. Y. H., Ellis, S. G., Kimura, T., Maeng, M., Merkely, B., Zeymer, U., Gropper, S., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1708454 · Cited by 1,383
Wood, A. M., Kaptoge, S., Butterworth, A. S., Willeit, P., Warnakula, S., Bolton, T., Paige, E., Paul, D. S., Sweeting, M., Burgess, S., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)30134-x · Cited by 1,188 · cited 5×
“This difference was driven primarily by a lower rate of non-fatal MI.”
BackgroundInfluentialSelf-citationMarine n−3 Fatty Acids and Prevention of Cardiovascular Disease and Cancer
Manson, J. E., Cook, N. R., Lee, I.-M., Christen, W., Bassuk, S. S., Mora, S., Gibson, H., Albert, C. M., Gordon, D., Copeland, T., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1811403 · Cited by 979 · cited 1×
“did not show a lower incidence of the primary cardiovascular composite outcome of MI, stroke, or cardiovascular death in either arm.(147) More data are needed to clarify the benefits of this class of drugs, also in higher dosages in cardiovascular event reduction.”
BackgroundSchoeppe, S., Alley, S., Van Lippevelde, W., Bray, N. A., Williams, S. L., Duncan, M. J., & Vandelanotte, C. (2016) · International Journal of Behavioral Nutrition and Physical Activity · doi:10.1186/s12966-016-0454-y · Cited by 949 · cited 1×
“Smartphone applications increase PA in children and adolescents.(115,116)”
BackgroundMustian, K. M., Alfano, C. M., Heckler, C., Kleckner, A. S., Kleckner, I. R., Leach, C. R., Mohr, D., Palesh, O. G., Peppone, L. J., Piper, B. F., et al. (2017) · JAMA Oncology · doi:10.1001/jamaoncol.2016.6914 · Cited by 932
Anand, S. S., Bosch, J., Eikelboom, J. W., Connolly, S. J., Diaz, R., Widimsky, P., Aboyans, V., Alings, M., Kakkar, A. K., Keltai, K., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32409-1 · Cited by 879
Rawshani, A., Sattar, N., Franzén, S., Rawshani, A., Hattersley, A. T., Svensson, A.-M., Eliasson, B., & Gudbjörnsdottir, S. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31506-x · Cited by 802 · cited 1×
“Similarly, recent evidence suggests that age of onset also matters to those with type 1 DM because it is associated with greater loss of life expectancy.(31) There is some evidence that people with type 1 DM have greater excess and absolute risks for CAD and heart failure (HF) than those with type 2 DM,(32) and thus t…”
BackgroundSelf-citationArmitage, J., Baigent, C., Barnes, E., Betteridge, D. J., Blackwell, L., Blazing, M., Bowman, L., Braunwald, E., Byington, R., Cannon, C., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(18)31942-1 · Cited by 801 · cited 1×
“A meta-analysis of data from all large statin trials to compare the effects of statin therapy at different ages showed significant reductions in major vascular events irrespective of age, but there is less direct evidence of benefit among patients older than 75 years who do not already have evidence of occlusive vascu…”
MethodSelf-citationZelniker, T. A., Wiviott, S. D., Raz, I., Im, K., Goodrich, E. L., Furtado, R. H. M., Bonaca, M. P., Mosenzon, O., Kato, E. T., Cahn, A., et al. (2019) · Circulation · doi:10.1161/circulationaha.118.038868 · Cited by 781 · cited 1×
“Such positive trials come either from the sodium-glucose cotransporter-2 (SGLT2) inhibitor class (empagliflozin, dapagliflozin or canagliflozin), as recently summarised in a meta-analysis,(148) or the glucagon-like peptide 1 (GLP-1) receptor agonist class of drugs (liraglutide, semaglutide, albiglutide, dulglutide) li…”
BackgroundConnolly, S. J., Eikelboom, J. W., Bosch, J., Dagenais, G., Dyal, L., Lanas, F., Metsarinne, K., O'Donnell, M., Dans, A. L., Ha, J.-W., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(17)32458-3 · Cited by 754
Koehler, F., Koehler, K., Deckwart, O., Prescher, S., Wegscheider, K., Kirwan, B.-A., Winkler, S., Vettorazzi, E., Bruch, L., Oeff, M., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31880-4 · Cited by 739
Caloric restriction reduces age-related and all-cause mortality in rhesus monkeys
Colman, R. J., Beasley, T. M., Kemnitz, J. W., Johnson, S. C., Weindruch, R., & Anderson, R. M. (2014) · Nature Communications · doi:10.1038/ncomms4557 · Cited by 711 · cited 1×
“Caloric restriction without malnutrition leads to increased longevity and delayed onset of age-associated disorders in rhesus monkeys.(122)”
BackgroundEffects of n−3 Fatty Acid Supplements in Diabetes Mellitus
The ASCEND Study Collaborative Group (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1804989 · Cited by 698
Physical activity, all-cause and cardiovascular mortality, and cardiovascular disease
KRAUS, W. E., POWELL, K. E., HASKELL, W. L., JANZ, K. F., CAMPBELL, W. W., JAKICIC, J. M., TROIANO, R. P., SPROW, K., TORRES, A., & PIERCY, K. L. (2019) · Medicine & Science in Sports & Exercise · doi:10.1249/mss.0000000000001939 · Cited by 671
Jakicic, J. M., Davis, K. K., Rogers, R. J., King, W. C., Marcus, M. D., Helsel, D., Rickman, A. D., Wahed, A. S., & Belle, S. H. (2016) · JAMA · doi:10.1001/jama.2016.12858 · Cited by 621
Environmental factors in cardiovascular disease
Cosselman, K. E., Navas-Acien, A., & Kaufman, J. D. (2015) · Nature Reviews Cardiology · doi:10.1038/nrcardio.2015.152 · Cited by 613
JBS3 Board (2014) · Heart · doi:10.1136/heartjnl-2014-305693 · Cited by 608
Nerenberg, K. A., Zarnke, K. B., Leung, A. A., Dasgupta, K., Butalia, S., McBrien, K., Harris, K. C., Nakhla, M., Cloutier, L., Gelfer, M., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.022 · Cited by 573
Natarajan, P., Young, R., Stitziel, N. O., Padmanabhan, S., Baber, U., Mehran, R., Sartori, S., Fuster, V., Reilly, D. F., Butterworth, A., et al. (2017) · Circulation · doi:10.1161/circulationaha.116.024436 · Cited by 570 · cited 1×
“A polygenic risk score derived from up to 57 common DNA sequence variants previously associated with CAD(18) has allowed us to identify individuals with a greater burden of subclinical atherosclerosis and who would derive a greater relative and absolute benefit from statin therapy to prevent a first CAD event.(19) It…”
BackgroundSelf-citationSattar, N., Rawshani, A., Franzén, S., Rawshani, A., Svensson, A.-M., Rosengren, A., McGuire, D. K., Eliasson, B., & Gudbjörnsdottir, S. (2019) · Circulation · doi:10.1161/circulationaha.118.037885 · Cited by 555
Self-citationSuglia, S. F., Koenen, K. C., Boynton-Jarrett, R., Chan, P. S., Clark, C. J., Danese, A., Faith, M. S., Goldstein, B. I., Hayman, L. L., Isasi, C. R., et al. (2018) · Circulation · doi:10.1161/cir.0000000000000536 · Cited by 518
Mente, A., O'Donnell, M., Rangarajan, S., Dagenais, G., Lear, S., McQueen, M., Diaz, R., Avezum, A., Lopez-Jaramillo, P., Lanas, F., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)30467-6 · Cited by 483
Sleep Apnea and Cardiovascular Disease: Lessons From Recent Trials and Need for Team Science
Drager, L. F., McEvoy, R. D., Barbe, F., Lorenzi-Filho, G., & Redline, S. (2017) · Circulation · doi:10.1161/circulationaha.117.029400 · Cited by 465 · cited 3×
“Epidemiological research indicates that obstructive sleep apnoea (OSA) is associated with increases in the incidence and progression of CAD, HF, stroke and AF.48 Central sleep apnoea associated with Cheyne–Stokes respiration (CSA-CSR) predicts incident HF and AF; among patients with HF, CSACSR strongly predicts mortal…”
BackgroundInfluentialStructured telephone support or non-invasive telemonitoring for patients with heart failure
Inglis, S. C., Clark, R. A., Dierckx, R., Prieto-Merino, D., & Cleland, J. G. (2015) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd007228.pub3 · Cited by 453
Hunter, R. F., Christian, H., Veitch, J., Astell-Burt, T., Hipp, J. A., & Schipperijn, J. (2015) · Social Science & Medicine · doi:10.1016/j.socscimed.2014.11.051 · Cited by 451 · cited 2×
“To decrease sedentary behaviours, moderate evidence suggests that school-based interventions targeting a reduction in television viewing and other screen-time activities, and worksite interventions including modifications to the workstation can have a positive impact.(84,86)”
BackgroundAssociation of Specific Dietary Fats With Total and Cause-Specific Mortality
Wang, D. D., Li, Y., Chiuve, S. E., Stampfer, M. J., Manson, J. E., Rimm, E. B., Willett, W. C., & Hu, F. B. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.2417 · Cited by 439
de Ferranti, S. D., Rodday, A. M., Mendelson, M. M., Wong, J. B., Leslie, L. K., & Sheldrick, R. C. (2016) · Circulation · doi:10.1161/circulationaha.115.018791 · Cited by 380 · cited 1×
“the modified Dutch Lipid Clinic Network criteria, which are based on non-genetic data, familial hypercholesterolemia is predicted to affect approximately one in 130–250 individuals worldwide; however, this condition is thought to be severely underdiagnosed in most countries.(57) The continuous relationship between BP…”
BackgroundBratton, D. J., Gaisl, T., Wons, A. M., & Kohler, M. (2015) · JAMA · doi:10.1001/jama.2015.16303 · Cited by 362
Gourlan, M., Bernard, P., Bortolon, C., Romain, A. J., Lareyre, O., Carayol, M., Ninot, G., & Boiché, J. (2016) · Health Psychology Review · doi:10.1080/17437199.2014.981777 · Cited by 353 · cited 6×
“There is now evidence that bouts of any duration, even less than 10 minutes, are effective and count for the daily/weekly volume target of PA.(84,110) There is moderate evidence that high intensity interval training can improve insulin sensitivity, BP and body composition similarly to aerobic continuous PA training, e…”
BackgroundInfluentialGuasch-Ferré, M., Satija, A., Blondin, S. A., Janiszewski, M., Emlen, E., O’Connor, L. E., Campbell, W. W., Hu, F. B., Willett, W. C., & Stampfer, M. J. (2019) · Circulation · doi:10.1161/circulationaha.118.035225 · Cited by 304
Galaviz, K. I., Weber, M. B., Straus, A., Haw, J. S., Narayan, K. M. V., & Ali, M. K. (2018) · Diabetes Care · doi:10.2337/dc17-2222 · Cited by 289 · cited 12×
“The ESC guideline1 emphasises the increased risk of the development of sustained hypertension and/ or DM in women who have had obstetric complications including pre-eclampsia, pregnancy-related hypertension and gestational DM.”
MethodInfluentialTada, H., Melander, O., Louie, J. Z., Catanese, J. J., Rowland, C. M., Devlin, J. J., Kathiresan, S., & Shiffman, D. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv462 · Cited by 285
Gravely, S., Giovino, G. A., Craig, L., Commar, A., D'Espaignet, E. T., Schotte, K., & Fong, G. T. (2017) · The Lancet Public Health · doi:10.1016/s2468-2667(17)30045-2 · Cited by 260 · cited 1×
“These measures should be regulated through robust legislation and rigorous enforcement, and have resulted in substantial prevalence declines of tobacco use in highincome countries.(92) A sign towards the opposite direction has been given in Austria: the smoking ban which was scheduled to begin in May 2018 in all bars…”
BackgroundMcAllister, D. A., Read, S. H., Kerssens, J., Livingstone, S., McGurnaghan, S., Jhund, P., Petrie, J., Sattar, N., Fischbacher, C., Kristensen, S. L., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034986 · Cited by 244
Self-citationLin, J. S., Evans, C. V., Johnson, E., Redmond, N., Coppola, E. L., & Smith, N. (2018) · JAMA · doi:10.1001/jama.2018.4242 · Cited by 216
Kim, J.-M., Stewart, R., Lee, Y.-S., Lee, H.-J., Kim, M. C., Kim, J.-W., Kang, H.-J., Bae, K.-Y., Kim, S.-W., Shin, I.-S., et al. (2018) · JAMA · doi:10.1001/jama.2018.9422 · Cited by 204 · cited 2×
“03).(158) Thus, treatment with SSRIs may improve subjective wellbeing and prognosis in depressed patients with CAD, but confirmation by additional trials is needed.”
BackgroundResultReavell, J., Hopkinson, M., Clarkesmith, D., & Lane, D. A. (2018) · Psychosomatic Medicine · doi:10.1097/psy.0000000000000626 · Cited by 189 · cited 1×
“Another meta-analysis showed the efficacy of cognitive psychotherapy for reducing psychological symptoms in patients with CVD and significant symptoms of depression and anxiety,(157) but there was no effect on cardiovascular events.(157) However, a recent trial has shown for the first time a favourable effect of antid…”
BackgroundPandey, A., Banerjee, S., Ngo, C., Mody, P., Marso, S. P., Brilakis, E. S., Armstrong, E. J., Giri, J., Bonaca, M. P., Pradhan, A., et al. (2017) · JACC: Cardiovascular Interventions · doi:10.1016/j.jcin.2017.01.027 · Cited by 89
Cited by
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab484 · Cited by 6,485
Self-citationStandards of Care for the Health of Transgender and Gender Diverse People, Version 8
Coleman, E., Radix, A. E., Bouman, W. P., Brown, G. R., de Vries, A. L. C., Deutsch, M. B., Ettner, R., Fraser, L., Goodman, M., Green, J., et al. (2022) · International Journal of Transgender Health · doi:10.1080/26895269.2022.2100644 · Cited by 2,698
2021 ESC Guidelines on cardiovascular disease prevention in clinical practice
Visseren, F. L. J., Mach, F., Smulders, Y. M., Carballo, D., Koskinas, K. C., Bäck, M., Benetos, A., Biffi, A., Boavida, J.-M., Capodanno, D., et al. (2022) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwab154 · Cited by 542
Self-citationJaarsma, T., Hill, L., Bayes‐Genis, A., La Rocca, H. B., Castiello, T., Čelutkienė, J., Marques‐Sule, E., Plymen, C. M., Piper, S. E., Riegel, B., et al. (2021) · European Journal of Heart Failure · doi:10.1002/ejhf.2008 · Cited by 538
Self-citationEarly-stage symptomatic osteoarthritis of the knee — time for action
Mahmoudian, A., Lohmander, L. S., Mobasheri, A., Englund, M., & Luyten, F. P. (2021) · Nature Reviews Rheumatology · doi:10.1038/s41584-021-00673-4 · Cited by 455
Metadata
- Authors
- Piepoli, M. F., Abreu, A., Albus, C., Ambrosetti, M., Brotons, C., Catapano, A. L., Corra, U., Cosyns, B., Deaton, C., Graham, I., Hoes, A., Lochen, M.-L., Matrone, B., Redon, J., Sattar, N., Smulders, Y., & Tiberi, M.
- Venue
- European Journal of Preventive Cardiology
- Publisher
- Oxford University Press (OUP)
- Published
- 2019-12-12
- Volume
- 27
- Issue
- 2
- Pages
- 181-205
- ISSN
- 2047-4873 (ISSN-L)
- 2047-4881
- OpenAlex
- W2995194925
- Cited by
- 220
- References
- 62
- FWCI
- 30.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.